Replies to post #109684 on Biotech Values

[genisi]

In Europe, Firazyr only sold $15M worth in 2010 but this should help sales:

European Commission Approves Self-Administration Label for FIRAZYR(R) (icatibant) for the Symptomatic Treatment of Acute Hereditary Angioedema Attacks

http://www.prnewswire.com/news-releases/european-commission-approves-self-administration-label-for-firazyrr-icatibant-for-the-symptomatic-treatment-of-acute-hereditary-angioedema-attacks-117306118.html